QSAM Biosciences Inc. announced that the first patient commenced treatment in its clinical trial evaluating CycloSam® in patients with metastatic bone cancer. QSAM previously announced the clearance of its IND by the U.S. Food and Drug Administration (FDA) and activation of clinical trial sites in its multi-center clinical trial for patients with bone cancer, including cancer that has metastasized from the lung, breast or prostate. Patients with cancer that originated in the bone including osteosarcoma and Ewing's sarcoma are also eligible to participate.

The study is a Phase 1 open-label, dose-escalation trial to evaluate the safety, tolerability, dosimetry, and preliminary efficacy of CycloSam®.